Bioshares Biotechnology Clinical Trials Fund ETF Forecast

Sell candidate since Jul 28, 2026 Loss -0.34%

The BioShares Biotechnology Clinical Trials ETF price gained 0.185% on the last trading day (Friday, 31st Jul 2026), rising from $48.62 to $48.71. During the last trading day the ETF fluctuated 0.83% from a day low at $48.31 to a day high of $48.71. The price has fallen in 6 of the last 10 days and is down by -4.43% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 1 thousand more shares were traded than the day before. In total, 14 thousand shares were bought and sold for approximately $699.43 thousand.

The ETF lies in the lower part of a wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $46.64 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the ETF is expected to rise 22.04% during the next 3 months and, with a 90% probability hold a price between $56.92 and $70.29 at the end of this 3-month period.

BBC Signals & Forecast

BioShares Biotechnology Clinical Trials has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The BioShares Biotechnology Clinical Trials ETF holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the ETF. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $49.24 and $49.65. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, July 09, 2026, and so far it has fallen -11.23%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for BioShares Biotechnology Clinical Trials ETF

On the downside, the ETF finds support just below today's level from accumulated volume at $46.00 and $44.83. There is a natural risk involved when a ETF is testing a support level, since if this is broken, the ETF then may fall to the next support level. In this case, BioShares Biotechnology Clinical Trials finds support just below today's level at $46.00. If this is broken, then the next support from accumulated volume will be at $44.83 and $41.06.

This ETF has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the ETF moved $0.400 between high and low, or 0.83%. For the last week, the ETF has had daily average volatility of 2.17%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (BBC) For The Upcoming Trading Day Of Monday 3rd

For the upcoming trading day on Monday, 3rd we expect BioShares Biotechnology Clinical Trials Fund to open at $48.58, and during the day (based on 14 day Average True Range), to move between $47.99 and $49.43, which gives a possible trading interval of +/-$1.43 (+/-2.98%) up or down from last closing price. If BioShares Biotechnology Clinical Trials Fund takes out the full calculated possible swing range there will be an estimated 2.98% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $50.97 (4.64%) than the support at $46.00 (5.56%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is BioShares Biotechnology Clinical Trials Fund ETF A Buy?

The BioShares Biotechnology Clinical Trials ETF holds several negative signals and despite the positive trend, we believe BioShares Biotechnology Clinical Trials will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this ETF.

Current score: -3.415 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on August 3, 2026 - $48.58 ( 0.274%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk